| A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias. | |
| | |
MedLine Citation:
|
PMID: 8638026 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial has recently shown the superiority of sotalol over class-1 agents in lowering the rate of recurrence of ventricular tachyarrhythmias. However, this study was not placebo-controlled, and amiodarone was not included as one of the antiarrhythmic drugs in the trial. Randomized comparative trials between sotalol and amiodarone are available, but the results are inconclusive mainly because of small sample sizes. Because of the specific pharmacokinetics of amiodarone, sotalol has become the first-line agent in the management of ventricular arrhythmias. Because this policy is based on expediency rather than follow-up data, the long-term efficacy, morbidity, and safety of sotalol should be compared with those of amiodarone as well as of nonpharmacological treatment modes for ventricular tachyarrhythmias, such as implantable cardioverter defibrillator therapy in prospective trials. Until these issues are resolved, it is incorrect to say that sotalol should be the first-line agent in the management of ventricular arrhythmias. |
| | |
Authors:
|
H Garan |
Related Documents
:
|
7317246 - Glycopyrrolate in children. 2596416 - Treatment of rhythm disorders by endocardial fulguration. 4008776 - Prevention of sudden death after repair of tetralogy of fallot: treatment of ventricula... 7084306 - Vertebral artery injection of ouabain does not hasten arrhythmogenesis. 8201786 - An autopsy case of hypertrophic cardiomyopathy with pathological findings suggesting ch... 20048196 - Sympathetic nervous system modulation of inflammation and remodeling in the hypertensiv... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Progress in cardiovascular diseases Volume: 38 ISSN: 0033-0620 ISO Abbreviation: Prog Cardiovasc Dis Publication Date: 1996 May-Jun |
Date Detail:
|
Created Date: 1996-07-11 Completed Date: 1996-07-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0376442 Medline TA: Prog Cardiovasc Dis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 455-6 Citation Subset: AIM; IM |
Affiliation:
|
Cardiac Unit, Massachusetts General Hospital, Boston, MA 02114, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use* Anti-Arrhythmia Agents / therapeutic use* Clinical Trials as Topic Humans Sotalol / therapeutic use* Tachycardia, Ventricular / drug therapy* Treatment Outcome Ventricular Fibrillation |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Anti-Arrhythmia Agents; 3930-20-9/Sotalol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventri...
Next Document: A perspective on the ESVEM trial and current knowledge: catheter ablation for ventricular tachyarrhy...